Ultime notizie per AB Corporate Bond ETF (NASDAQ:EYEG)

The Fund is an actively-managed exchange-traded fund (ETF). The Fund pursues its objective by investing, under normal circumstances, at least 80% of its net assets, including any borrowings for investment purposes, in investment grade fixed-income securities of corporate issuers. Corporate issuers may include corporate or other business entities in which a sovereign or governmental agency or entity may have, indirectly or directly, an interest, including a majority or greater ownership interest.

AB Corporate Bond ETF

<h3>Gainers</h3>
<ul>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock increased by 43.11% to $6.44 during Friday's pre-market session. The market value of their outstanding shares is at $80.5 million. </li>
<li>Atea Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVIR#NASDAQ">AVIR</a>) stock rose 29.63% to $45.45. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Progenity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROG#NASDAQ">PROG</a>) shares moved upwards by 24.99% to $1.9. The market value of their outstanding shares is at $226.8 million. </li>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) stock moved upwards by 15.32% to $0.64. The market value of their outstanding shares is at $117.7 million. </li>
<li>Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) stock rose 7.7% to $80.9. The company's market cap stands at $204.7 billion. </li>
<li>Vyant Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNT#NASDAQ">VYNT</a>) shares moved upwards by 7.29% to $2.5. The market value of their outstanding shares is at $72.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NeuroBo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRBO#NASDAQ">NRBO</a>) stock fell 13.98% to $3.2 during Friday's pre-market session. The market value of their outstanding shares is at $71.3 million. </li>
<li>Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) shares decreased by 12.69% to $38.0. The market value of their outstanding shares is at $4.9 billion. </li>
<li>Adagio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGI#NASDAQ">ADGI</a>) stock declined by 12.41% to $37.0. The company's market cap stands at $4.1 billion. </li>
<li>Allied Healthcare Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHPI#NASDAQ">AHPI</a>) stock fell 7.11% to $6.41. The market value of their outstanding shares is at $25.7 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) shares decreased by 6.34% to $9.31. The company's market cap stands at $57.1 million. </li>
<li>Eyegate Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEG#NASDAQ">EYEG</a>) shares declined by 6.23% to $2.11. The company's market cap stands at $26.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>

Movers

ADGI

AHPI

AVIR

BMRA

EYEG

ITRM

NRBO

PROG

SNPX

VYNT

12 Health Care Stocks Moving In Friday's Pre-Market Session

<a href="https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=1&amp;f=G&amp;l=50&amp;co1=AND&amp;d=PG01&amp;s1=20210299039&amp;OS=20210299039&amp;RS=20210299039" title="https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=1&amp;f=G&amp;l=50&amp;co1=AND&amp;d=PG01&amp;s1=20210299039&amp;OS=20210299039&amp;RS=20210299039">https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=1&amp;f=G&amp;l=50&amp;co1=AND&amp;d=PG01&amp;s1=20210299039&amp;OS=20210299039&amp;RS=20210299039</a>

News

Eyegate Pharmaceuticals Files For Patent Application Titled 'COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE BY CONTACT LENS MEDIATED DRUG DELIVERY'

&nbsp;
<h3>Gainers</h3>
<ul>
<li>Progenity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROG#NASDAQ">PROG</a>) stock increased by 21.06% to $1.31 during Thursday&#39;s regular session. The current volume of 70.4 million shares is 943.37% of Progenity&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The company&#39;s market cap stands at $156.1 million.</li>
<li>Atea Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVIR#NASDAQ">AVIR</a>) shares increased by 16.23% to $37.34. As of 12:30 EST, this security is trading at a volume of 2.8 million shares, making up 207.79% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.0 billion.</li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 12.72% to $84.5. The current volume of 1.2 million shares is 739.74% of OptimizeRx&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $1.4 billion.</li>
<li>AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) stock increased by 11.64% to $26.08. As of 12:30 EST, this security is trading at a volume of 494.9K shares, making up 205.38% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.0 billion. As per the news, the Q1 earnings report came out today.</li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRA#NASDAQ">BFRA</a>) shares moved upwards by 9.31% to $5.75. The company&#39;s market cap stands at $163.0 million.</li>
<li>Eyegate Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEG#NASDAQ">EYEG</a>) stock moved upwards by 9.29% to $2.0. As of 12:30 EST, this security is trading at a volume of 6.5 million shares, making up 285.85% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $25.2 million.</li>
</ul>
&nbsp;
&nbsp;
<h3>Losers</h3>
&nbsp;
<ul>
<li>Corvus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares fell 19.62% to $5.08 during Thursday&#39;s regular session. Trading volume for this security as of 12:30 EST is 5.4 million, which is 72.65% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $215.5 million.</li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) shares declined by 13.63% to $11.35. The company&#39;s market cap stands at $1.6 billion.</li>
<li>ChemoCentryx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCXI#NASDAQ">CCXI</a>) stock fell 13.22% to $16.98. Trading volume for ChemoCentryx&#39;s stock is 2.5 million as of 12:30 EST. This is 125.79% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $1.1 billion.</li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock fell 12.59% to $2.43. As of 12:30 EST, NuCana&#39;s stock is trading at a volume of 2.7 million, which is 167.47% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $126.7 million.</li>
<li>CNS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock declined by 11.26% to $1.42. As of 12:30 EST, this security is trading at a volume of 1.1 million shares, making up 238.2% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $38.9 million.</li>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares declined by 10.99% to $0.54. The current volume of 6.8 million shares is 71.39% of Iterum Therapeutics&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The company&#39;s market cap stands at $99.2 million. 
	See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
&nbsp;
&nbsp;

Intraday Update

Markets

ANGO

BFRA

CCXI

CNSP

CRVS

HLTH

NCNA

OPRX

12 Health Care Stocks Moving In Thursday's Intraday Session

By <a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=b8877843-0e4b-47b2-895e-10adc4acf236">Beth Senko, CFA</a>
<stock_ticker>NASDAQ:EYEG</stock_ticker>
<a href="https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_09302021_EYEG_Senko.pdf">READ THE FULL EYEG RESEARCH REPORT</a>
The past year has been one of much change at EyeGate Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eyeg#NASDAQ">EYEG</a>). The pipeline has expanded from one to three candidates (with multiple possible indications). The Company has raised over $20 million in funding and added key clinical and management hires. We expect a series of clinical milestones over the next 12-18 months to help refocus attention on an underappreciated company.
In early September, EYEG completed enrollment of 21 patients for its Phase 2 clinical trial to treat dry eye disease with its first-in-class dihydroorotate dehydrogenase ("DHODH") inhibitor, PP-001. This study follows a Phase 1 safety and dose escalation study in 24 healthy volunteers. The Phase 2 study is expected to report top-line data in Q421. 
The FDA changed the designation for EYEG's Ocular Bandage Gel (OBG) candidate from a medical device to a drug. OBG is in development for ophthalmic wounds either post-surgery, or from injury. OBG may also be of value in treating dry eye. The upside to the regulatory reclassification is that OBG will be eligible for reimbursement under Medicare Part D plans; however, EYEG needs to redesign its clinical trials to meet the new approval criteria. EYEG plans to start a proof-of-concept study in Q421.
Finally, in July, EyeGate signed a letter of intent to acquire Bayon Therapeutics, a private, clinical-stage ophthalmic pharmaceutical company working with light-sensitive molecules as potential treatment for patients with degenerative retinal diseases. In 2Q22, EYEG will have a pre-IND meeting for Bayon's lead candidate, B-203, and plans to initiate a Phase 1b proof-of-concept study in retinitis pigmentosa.
In August, EyeGate raised $9.7 million net proceeds in a direct offering of 4.7 million shares at $2.30 per share. Separately, the Company issued 2.3 million warrants with an exercise price of $2.24 per share. At June 30, 2021, cash and cash equivalents were $3.7 million compared to $1.2 million at the end of December. The increase in cash and cash equivalents was mainly due to net proceeds of $7.989 million received from the completion of a private placement in January of 2021, partially offset by cash outflows to fund the Company's operations. 
In the second quarter, research and development expenses were $1.4 million, compared to $0.6 million in the year-earlier period. The increase was primarily due to the December 2020, Panoptes acquisition, including development costs for PP-001 and personnel related costs, partially offset by a decrease in costs related to OBG. 
General and administrative expenses were $1.3 million for the second quarter, compared to $1.1 million in 2Q20. The increase was primarily due to increases in professional fees and personnel related costs. 
<a href="http://scr.zacks.com/Subscribe/defaultaspx/ default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;">SUBSCRIBE TO ZACKS SMALL CAP RESEARCH</a> to receive our articles and reports emailed directly to you each morning. Please visit our <a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;">website</a> for additional information on Zacks SCR. 
 
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer <a href="https://scr.zacks.com/home/default.aspx" style="color: rgb(242, 132, 16);">HERE</a>.

Penny Stocks

EYEG: Refreshed and moving forward

Price Target

Analyst Ratings

Trading Ideas

Eyegate Pharmaceuticals Shares See Volume, Hearing Zacks Small-Cap Research Out With $15 Price Target

<a href="https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&amp;r=7687&amp;p=154&amp;f=G&amp;l=50&amp;d=PG01&amp;S1=20210923.PD.&amp;OS=PD/20210923&amp;RS=PD/20210923" title="https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&amp;r=7687&amp;p=154&amp;f=G&amp;l=50&amp;d=PG01&amp;S1=20210923.PD.&amp;OS=PD/20210923&amp;RS=PD/20210923">https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&amp;r=7687&amp;p=154&amp;f=G&amp;l=50&amp;d=PG01&amp;S1=20210923.PD.&amp;OS=PD/20210923&amp;RS=PD/20210923</a>

Legal

EyeGate Pharma US Patent & Trademark Office Abstract For Co.'s 'Compositions and Methods for Treatment of Ocular Conditions'

<h3>Gainers</h3>
<ul>
<li>Communications Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jcs#NASDAQ">JCS</a>) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share.</li>
<li>Onion Global Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/og#NYSE">OG</a>) jumped 30.6% to close at $7.30 after dropping 18% on Monday.</li>
<li>Cyren Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyrn#NASDAQ">CYRN</a>) jumped 26.7% to close at $0.7363 after the company reported a distribution agreement with TD SYNNEX to offer its anti-phishing solution throughout North America.</li>
<li>Gaucho Group Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vino#NASDAQ">VINO</a>) gained 25.8% to close at $3.95 after the company announced it will acquire additional real estate assets in Argentina for $2.4 million.</li>
<li>NanoViricides, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nnvc#NYSE">NNVC</a>) rose 18.7% to settle at $4.83 after the company announced it completed the process of licensing the human Coronavirus field for drug development and commercialization from TheraCour Pharma, Inc.</li>
<li>Calumet Specialty Products Partners, L.P., (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clmt#NASDAQ">CLMT</a>) jumped 17.4% to close at $7.21 after declining 20% on Monday.</li>
<li>Kezar Life Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kzr#NASDAQ">KZR</a>) gained 17.4% to close at $8.97.</li>
<li>BELLUS Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blu#NASDAQ">BLU</a>) shares gained 16.5% to settle at $5.57. The company on Monday announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractor chronic cough. HC Wainwright on Tuesday raised its price target on the stock.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) jumped 15.1% to close at $12.64 after IQVIA announced a collaboration with the company on potential medical support for novel COVID-19 treatment.</li>
<li>Adagio Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adgi#NASDAQ">ADGI</a>) gained 14.8% to settle at $49.37.</li>
<li>FuelCell Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fcel#NASDAQ">FCEL</a>) shares surged 14.6% to close at $6.44 on Tuesday after the company reported better-than-expected Q3 results.</li>
<li>DatChat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dats#NASDAQ">DATS</a>) gained 13.2% to settle at $7.40 after gaining around 4% on Monday.</li>
<li>PyroGenesis Canada Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyr#NASDAQ">PYR</a>) surged 12.6% to close at $4.55 as the company received an order to supply four high-powered plasma torches together with ancillary equipment to a client for approximately $6 million. The name of the client, a multi-billion-dollar international producer of iron ore, was not disclosed.</li>
<li>Matinas BioPharma Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtnb#NASDAQ">MTNB</a>) gained 12.4% to close at $1.18. Matinas BioPharma shares climbed 27% on Monday after the company announced data in the ongoing EnACT trial of MAT2203 for treatment of Cryptococcal Meningitis.</li>
<li>Jounce Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jnce#NASDAQ">JNCE</a>) gained 11.9% to close at $7.24. Raymond James upgraded Jounce Therapeutics from Market Perform to Outperform and announced a $10 price target.</li>
<li>Imago BioSciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imgo#NASDAQ">IMGO</a>) rose 10.9% to close at $28.01.</li>
<li>Angi Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/angi#NASDAQ">ANGI</a>) gained 9.2% to close at $11.68. IAC posted monthly metrics for August 2021, including metrics for Angi Inc, in the investor relations section of the IAC website.</li>
<li>Crocs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crox#NASDAQ">CROX</a>) jumped 8.5% to settle at $149.38 following news from the company&#39;s Investor Day today. The company also announced it expects Crocs brand to grow to over $5 billion in sales by 2026.</li>
<li>AzurRx BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azrx#NASDAQ">AZRX</a>) surged 8.1% to close at $4.43 after the company announced acquisition of First Wave Bio for $229 million in stock and cash.</li>
<li>EyeGate Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eyeg#NASDAQ">EYEG</a>) rose 7.1% to close at $1.80. EyeGate Pharma recently completed target enrollment in Phase 2 proof-of-concept study to evaluate PP-001 for the treatment of ocular surface inflammation.</li>
<li>Alset EHome International Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aei#NASDAQ">AEI</a>) gained 5.6% to close at $3.00. The company recently announced the completion of a subscription agreement with Document Security Systems.</li>
<li>Gulf Resources, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gure#NASDAQ">GURE</a>) rose 5.3% to close at $4.38. Gulf Resources said it sees Q3 revenue of $16.2 million to $16.7 million.</li>
</ul>
&nbsp;

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>
<h3>Losers</h3>
<ul>
<li>Aterian, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ater#NASDAQ">ATER</a>) fell 39% to close at $10.96 after jumping 52% on Monday.</li>
<li>Support.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprt#NASDAQ">SPRT</a>) shares dipped 38.2% to close at $11.80 after dropping 9% on Monday. The stock has been circulated as a potential short squeeze candidate on social media.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrpx#NASDAQ">VRPX</a>) shares tumbled 36.8% to close at $6.16 on Tuesday after the company priced a 6.67 million share common stock offering at $6 per share.</li>
<li>RedHill Biopharma Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdhl#NASDAQ">RDHL</a>) declined 32.7% to close at $4.97 after the company announced preliminary top-line data from the Phase 2/3 study with opaganib showed that the study did not meet its primary endpoint.</li>
<li>Focus Universal Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fcuv#NASDAQ">FCUV</a>) fell 25.1% to close at $9.90.</li>
<li>Globalstar, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gsat#NASDAQ">GSAT</a>) dropped 23.3% to settle at $1.75 following Apple&#39;s fall hardware event. Traders were optimistic about Globalstar working with Apple to implement satellite capabilities to iPhones.</li>
<li>eFFECTOR Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eftr#NASDAQ">EFTR</a>) declined 22.3% to close at $20.76. Cantor Fitzgerald, on Monday, initiated coverage on the stock with an Overweight rating and a $50 price target.</li>
<li>Herbalife Nutrition Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NYSE">HLF</a>) dipped 21.1% to close at $42.78 after the company revised its guidance for the third quarter and full year 2021. The company said it sees Q3 adjusted earnings of $1.00 to $1.20 per share. Herbalife updated its full year adjusted earnings guidance to a range of $4.55 to $4.95 per share, while adjusted EBITDA is being lowered to a range of $860 million to $910 million.</li>
<li>PAR Technology Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/par#NYSE">PAR</a>) fell 18.1% to settle at $56.01 after the company reported proposed offerings of 1.5 million shares common stock and $200 million of convertible senior notes.</li>
<li>ATIF Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atif#NASDAQ">ATIF</a>) dipped 17.2% to close at $3.61.</li>
<li>Vinco Ventures, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbig#NASDAQ">BBIG</a>) dropped 17.1% to close at $7.95.</li>
<li>BRP Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brp#NYSE">BRP</a>) dipped 16.9% to close at $31.27 as the company reported a proposed public offering of 8 million shares of common stock.</li>
<li>HyreCar Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hyre#NASDAQ">HYRE</a>) dropped 16.4% to settle at $10.27.</li>
<li>Arqit Quantum Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arqq#NASDAQ">ARQQ</a>) shares declined 16% to close at $12.59.</li>
<li>Evaxion Biotech A/S (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evax#NASDAQ">EVAX</a>) dropped 15.6% to settle at $7.60.</li>
<li>Data Storage Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtst#NASDAQ">DTST</a>) declined 14.5% to close at $5.41.</li>
<li>MICT, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mict#NASDAQ">MICT</a>) fell 14% to close at $1.91.</li>
<li>Vallon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlon#NASDAQ">VLON</a>) shares dropped 13.9% to close at $7.10. Vallon Pharmaceuticals announced the formation of scientific advisory board.</li>
<li>Calliditas Therapeutics AB (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calt#NASDAQ">CALT</a>) fell 13.8% to close at $24.48. Calliditas Therapeutics said the FDA has extended PDUFA goal date for nefecon.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) shares fell 12.5% to close at $20.18.</li>
<li>Cassava Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sava#NASDAQ">SAVA</a>) declined 11.3% to close at $41.79.</li>
<li>Wynn Resorts, Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wynn#NASDAQ">WYNN</a>) dropped 10.9% to close at $92.25 amid reports of increased government oversight of casinos in Macau.</li>
<li>Las Vegas Sands Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lvs#NYSE">LVS</a>) declined 9.8% to close at $38.71 amid reports of increased government oversight of casinos in Macau.</li>
<li>Aluminum Corporation of China Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ach#NYSE">ACH</a>) fell 6.6% to settle at $21.72 after gaining over 8% on Monday.</li>
</ul>

Small Cap

Pre-Market Outlook

ANGI

ARQQ

ATER

ATIF

AZRX

BBIG

CALT

CLMT

CROX

CYRN

DATS

DTST

EFTR

EVAX

FCEL

FCUV

GSAT

GURE

HYRE

IMGO

JNCE

MICT

MTNB

NNVC

NRXP

RDHL

RNLX

SAVA

SPRT

VINO

VLON

VRPX

WYNN

46 Biggest Movers From Yesterday

<h3>Gainers</h3>
<ul>
<li>FuelCell Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fcel#NASDAQ">FCEL</a>) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results.</li>
<li>BELLUS Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blu#NASDAQ">BLU</a>) shares climbed 25.5% to $6.00. The company on Monday announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractor chronic cough. HC Wainwright on Tuesday raised its price target on the stock.</li>
<li>BTCS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btcs#NASDAQ">BTCS</a>) shares climbed 23% to $10.25 as the company commenced trading on The Nasdaq Capital Market.</li>
<li>Communications Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jcs#NASDAQ">JCS</a>) gained 22.3% to $8.25 as the company declared a special dividend of $3.50 per share.</li>
<li>aTyr Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/life#NASDAQ">LIFE</a>) shares jumped 22.3% to $11.19 after multiple firms maintained bullish ratings on the stock and raised their respective price targets. aTyr Pharma shares jumped 67% on Monday after the company announced the Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis met its primary endpoint.</li>
<li>DatChat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dats#NASDAQ">DATS</a>) rose 22.2% to $7.99 after gaining around 4% on Monday.</li>
<li>Onion Global Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/og#NYSE">OG</a>) gained 17.3% to $6.55 after dropping 18% on Monday.</li>
<li>NanoViricides, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nnvc#NYSE">NNVC</a>) rose 17.2% to $4.7706 after the company announced it completed the process of licensing the human Coronavirus field for drug development and commercialization from TheraCour Pharma, Inc.</li>
<li>Gulf Resources, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gure#NASDAQ">GURE</a>) gained 16.4% to $4.84. Gulf Resources said it sees Q3 revenue of $16.2 million to $16.7 million.</li>
<li>Matinas BioPharma Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtnb#NASDAQ">MTNB</a>) rose 16.2% to $1.2205. Matinas BioPharma shares climbed 27% on Monday after the company announced data in the ongoing EnACT trial of MAT2203 for treatment of Cryptococcal Meningitis.</li>
<li>AzurRx BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azrx#NASDAQ">AZRX</a>) gained 15.9% to $4.75 after the company announced acquisition of First Wave Bio for $229 million in stock and cash.</li>
<li>Calumet Specialty Products Partners, L.P., (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clmt#NASDAQ">CLMT</a>) surged 14% to $7.00 after declining 20% on Monday.</li>
<li>Jounce Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jnce#NASDAQ">JNCE</a>) surged 13.8%to $7.36 Raymond James upgraded Jounce Therapeutics from Market Perform to Outperform and announced a $10 price target.</li>
<li>Alset EHome International Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aei#NASDAQ">AEI</a>) gained 9.1% to $3.0999. The company recently announced the completion of a subscription agreement with Document Security Systems.</li>
<li>Cyren Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyrn#NASDAQ">CYRN</a>) rose 8.6% to $0.6310 after the company reported a distribution agreement with TD SYNNEX to offer its anti-phishing solution throughout North America.</li>
<li>Angi Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/angi#NASDAQ">ANGI</a>) gained 8.3% to $11.59. IAC posted monthly metrics for August 2021, including metrics for Angi Inc, in the investor relations section of the IAC website.</li>
<li>Oscar Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oscr#NYSE">OSCR</a>) rose 7% to $18.30. Oscar Health Co-Founder Joshua Kushner reported the purchase of 1,072,264 shares at an average price of $17.41 per share in Form 4 Filing.</li>
<li>Akerna Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kern#NASDAQ">KERN</a>) rose 6.3% to $3.5199. The company agreed to acquire 365 Cannabis, a cannabis business management software system built on Microsoft&#39;s Dynamics 365 Business Central in a $17 million deal.</li>
<li>EyeGate Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eyeg#NASDAQ">EYEG</a>) rose 6.3% to $1.7850. EyeGate Pharma recently completed target enrollment in Phase 2 proof-of-concept study to evaluate PP-001 for the treatment of ocular surface inflammation.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) rose 5% to $11.53 after IQVIA announced a collaboration with the company on potential medical support for novel COVID-19 treatment.</li>
</ul>

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrpx#NASDAQ">VRPX</a>) shares dipped 37.2% to $6.13 after the company priced a 6.67 million share common stock offering at $6 per share.</li>
<li>RedHill Biopharma Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdhl#NASDAQ">RDHL</a>) fell 33% to $4.9487 after the company announced preliminary top-line data from the Phase 2/3 study with opaganib showed that the study did not meet its primary endpoint.</li>
<li>Aterian, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ater#NASDAQ">ATER</a>) dropped 21.7% to $14.08 after jumping 52% on Monday.</li>
<li>eFFECTOR Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eftr#NASDAQ">EFTR</a>) fell 19.7% to $21.45. Cantor Fitzgerald, on Monday, initiated coverage on the stock with an Overweight rating and a $50 price target.</li>
<li>Support.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprt#NASDAQ">SPRT</a>) shares fell 15.8% to $16.09 after dropping 9% on Monday. The stock has been circulated as a potential short squeeze candidate on social media.</li>
<li>PAR Technology Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/par#NYSE">PAR</a>) fell 15.5% to $57.77 after the company reported proposed offerings of 1.5 million shares common stock and $200 million of convertible senior notes.</li>
<li>Herbalife Nutrition Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NYSE">HLF</a>) dipped 15.1% to $46.06 after the company revised its guidance for the third quarter and full year 2021. The company said it sees Q3 adjusted earnings of $1.00 to $1.20 per share. Herbalife updated its full year adjusted earnings guidance to a range of $4.55 to $4.95 per share, while adjusted EBITDA is being lowered to a range of $860 million to $910 million.</li>
<li>BRP Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brp#NYSE">BRP</a>) dipped 13.6% to $32.53 as the company reported a proposed public offering of 8 million shares of common stock.</li>
<li>Las Vegas Sands Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lvs#NYSE">LVS</a>) fell 13.1% to $37.28 amid reports of increased government oversight of casinos in Macau.</li>
<li>Vinco Ventures, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbig#NASDAQ">BBIG</a>) fell 12.3% to $8.41.</li>
<li>Focus Universal Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fcuv#NASDAQ">FCUV</a>) dropped 12% to $11.63.</li>
<li>Wynn Resorts, Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wynn#NASDAQ">WYNN</a>) fell 11.5% to $91.60 amid reports of increased government oversight of casinos in Macau.</li>
<li>MICT, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mict#NASDAQ">MICT</a>) dropped 10.1% to $1.9950.</li>
<li>Cassava Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sava#NASDAQ">SAVA</a>) fell 8.4% to $43.17.</li>
<li>Aluminum Corporation of China Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ach#NYSE">ACH</a>) fell 6.7% to $21.70 after gaining over 8% on Monday.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) shares fell 6.1% to $21.65.</li>
</ul>

BTCS

KERN

LIFE

OSCR

36 Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Communications Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jcs#NASDAQ">JCS</a>) rose 34.8% to $9.15 in pre-market trading as the company declared a special dividend of $3.50 per share.</li>
<li>DatChat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dats#NASDAQ">DATS</a>) rose 16.2% to $7.60 in pre-market trading after gaining around 4% on Monday.</li>
<li>Akerna Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kern#NASDAQ">KERN</a>) rose 11.5% to $3.69 in pre-market trading. The company agreed to acquire 365 Cannabis, a cannabis business management software system built on Microsoft&#39;s Dynamics 365 Business Central in a $17 million deal.</li>
<li>PainReform Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prfx#NASDAQ">PRFX</a>) rose 10.8% to $3.11 in pre-market trading.</li>
<li>NanoViricides, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nnvc#NYSE">NNVC</a>) rose 10.5% to $4.50 in pre-market trading after the company said it completed licensing for coronavirus field which included current covid-19 drug development.</li>
<li>aTyr Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/life#NASDAQ">LIFE</a>) shares rose 10.3% to $10.09 in pre-market trading. aTyr Pharma shares jumped 67% on Monday after the company announced the Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis met its primary endpoint.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) rose 10% to $12.08 in pre-market trading after IQVIA announced a collaboration with the company on potential medical support for novel COVID-19 treatment.</li>
<li>Cyren Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyrn#NASDAQ">CYRN</a>) rose 9% to $0.6330 in pre-market trading. Cyren and Improving recently reported a partnership to &#39;strengthen phishing defense for Microsoft 365.&#39;</li>
<li>Oscar Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oscr#NYSE">OSCR</a>) rose 9% to $18.64 in pre-market trading. Oscar Health Co-Founder Joshua Kushner reported the purchase of 1,072,264 shares at an average price of $17.41 per share in Form 4 Filing.</li>
<li>IN8bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inab#NASDAQ">INAB</a>) rose 8.8% to $9.63 in pre-market trading. IN8BIO recently reported a net loss of $1.00 per share for the second quarter, versus a year-ago loss of $0.92 per share.</li>
<li>Amryt Pharma plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amyt#NASDAQ">AMYT</a>) rose 7.7% to $11.50 in pre-market trading. Amryt boosted full year 2021 revenue guidance to $220 million - $225 million.</li>
<li>Ur-Energy Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/urg#NYSE">URG</a>) rose 6.7% to $1.90 in pre-market trading after climbing over 7% on Monday.</li>
<li>EyeGate Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eyeg#NASDAQ">EYEG</a>) rose 6% to $1.78 in pre-market trading. EyeGate Pharma recently completed target enrollment in Phase 2 proof-of-concept study to evaluate PP-001 for the treatment of ocular surface inflammation.</li>
<li>Matinas BioPharma Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtnb#NASDAQ">MTNB</a>) rose 5.7% to $1.11 in pre-market trading. Matinas BioPharma shares climbed 27% on Monday after the company announced data in the ongoing EnACT trial of MAT2203 for treatment of Cryptococcal Meningitis.</li>
<li>Markforged Holding Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mkfg#NYSE">MKFG</a>) shares rose 5.5% to $8.06 in pre-market trading after dropping 5% on Monday.</li>
</ul>
Find out what&#39;s going on in today&#39;s market and bring any questions you have to <a href="http://premarket.benzinga.com/pre-market-show/">Benzinga&#39;s PreMarket Prep</a>.
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>
<h3>Losers</h3>
<ul>
<li>TMC the metals company Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmc#NASDAQ">TMC</a>) shares fell 10.8% to $11.10 in pre-market trading after jumping 32% on Monday.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) shares fell 7.4% to $21.35 in pre-market trading.</li>
<li>Old Republic International Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ori#NYSE">ORI</a>) shares fell 5.5% to $23.73 in pre-market trading.</li>
<li>Support.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprt#NASDAQ">SPRT</a>) shares fell 5% to $18.16 in pre-market trading after dropping 9% on Monday. The stock has been circulated as a potential short squeeze candidate on social media.</li>
<li>Aluminum Corporation of China Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ach#NYSE">ACH</a>) fell 5% to $22.09 in pre-market trading after gaining over 8% on Monday.</li>
</ul>

AMYT

INAB

MKFG

PRFX

20 Stocks Moving in Tuesday's Pre-Market Session

EyeGate Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEG#NASDAQ">EYEG</a>), (&quot;EyeGate&quot; or the &quot;Company&quot;), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed target enrollment of 21 patients in the Phase 2 proof-of-concept (&quot;POC&quot;) study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase (&quot;DHODH&quot;) and is first-in-class for ophthalmology indications.
&quot;This is an important clinical milestone and step forward in advancing PP-001 as a new treatment option for patients with dry eye and a range of ocular surface and systemic diseases,&quot; said Brian Strem, Ph.D., President and Chief Executive Officer of EyeGate. &quot;We believe our proof-of-concept study will further validate the clinical utility of PP-001, which has the potential to overcome off-target side effects and safety issues associated with DHODH inhibitors with greater specificity and best-in-class picomolar potency. Additionally, this study will inform our clinical strategy for dry eye disease in the U.S. and more broadly, guide the development of our pipeline programs as we explore opportunities to maximize the therapeutic potential of our platform. We look forward to providing topline data in&nbsp;Q4&nbsp;2021.&quot;
The randomized, double-masked, placebo-controlled POC study conducted at a site in Vienna, Austria is designed to evaluate the safety, tolerability, and efficacy of PP-001 in patients with ocular surface inflammation due to dry eye disease. In this study, a total of 21 patients are treated for 12 days with&nbsp;0.15%&nbsp;of PP-001 or placebo. An IND filing for dry eye disease in the U.S. is expected in&nbsp;Q4&nbsp;2021.

Biotech

General

EyeGate Pharma Completes Target Enrollment In Phase 2 Proof-Of-Concept Study To Evaluate PP-001 For The Treatment Of Ocular Surface Inflammation

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:
<h3>Scaling The Peaks</h3>
(Biotech Stocks Hitting 52-week Highs Aug. 18)
<ul>
<li>AbbVie Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abbv#NYSE">ABBV</a>)</li>
<li>Alkermes plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alks#NASDAQ">ALKS</a>)</li>
<li>Bio-Rad Laboratories, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bio#NYSE">BIO</a>)</li>
<li>Crinetics Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crnx#NASDAQ">CRNX</a>)</li>
<li>Gilead Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gild#NASDAQ">GILD</a>)</li>
<li>GlaxoSmithKline plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gsk#NYSE">GSK</a>) (<a href="https://www.benzinga.com/general/biotech/21/08/22553371/the-daily-biotech-pulse-azurrx-jumps-on-data-agios-regulatory-application-for-mitapivat-accepted-">announced </a> FDA approval for label expansion for its Jemperli)</li>
<li>Novo Nordisk A/S (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvo#NYSE">NVO</a>)</li>
<li>Innoviva, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inva#NASDAQ">INVA</a>)</li>
<li>Intuitive Surgical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>)</li>
<li>Maravai LifeSciences Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvi#NASDAQ">MRVI</a>)</li>
<li>Omega Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omga#NASDAQ">OMGA</a>) (IPOed July 30)</li>
<li>Pfizer, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>)</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>)</li>
<li>ResMed Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>)</li>
<li>TScan Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcrx#NASDAQ">TCRX</a>)</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrpx#NASDAQ">VRPX</a>)</li>
<li>West Pharmaceutical Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wst#NYSE">WST</a>)</li>
</ul>
<h3>Down In The Dumps</h3>
(Biotech Stocks Hitting 52-week Lows Aug. 18)
<ul>
<li>Absci Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/absi#NASDAQ">ABSI</a>)</li>
<li>Achieve Life Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achv#NASDAQ">ACHV</a>)</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adpt#NASDAQ">ADPT</a>)</li>
<li>ADMA Biologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>)</li>
<li>Akouos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akus#NASDAQ">AKUS</a>)</li>
<li>Angion Biomedica Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/angn#NASDAQ">ANGN</a>)</li>
<li>Aptinyx Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aptx#NASDAQ">APTX</a>)</li>
<li>Arena Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arna#NASDAQ">ARNA</a>)</li>
<li>AVROBIO, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avro#NASDAQ">AVRO</a>)</li>
<li>Axsome Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axsm#NASDAQ">AXSM</a>)</li>
<li>Biomea Fusion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmea#NASDAQ">BMEA</a>)</li>
<li>BiondVax Pharmaceuticals Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bvxv#NASDAQ">BVXV</a>)</li>
<li>Catalyst Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cbio#NASDAQ">CBIO</a>)</li>
<li>Checkmate Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmpi#NASDAQ">CMPI</a>)</li>
<li>Chemomab Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmmb#NASDAQ">CMMB</a>)</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnsp#NASDAQ">CNSP</a>)</li>
<li>Compass Therapeutics, Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/cmpx#OTC">CMPX</a>)</li>
<li>ContraFect Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cfrx#NASDAQ">CFRX</a>)</li>
<li>CymaBay Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cbay#NASDAQ">CBAY</a>)</li>
<li>CytomX Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctmx#NASDAQ">CTMX</a>)</li>
<li>Epizyme, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/epzm#NASDAQ">EPZM</a>)</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>)</li>
<li>EyeGate Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eyeg#NASDAQ">EYEG</a>)</li>
<li>FibroGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fgen#NASDAQ">FGEN</a>)</li>
<li>Flexion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flxn#NASDAQ">FLXN</a>)</li>
<li>Heron Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hrtx#NASDAQ">HRTX</a>)</li>
<li>IN8bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inab#NASDAQ">INAB</a>) (IPOed July 30)</li>
<li>iRhythm Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irtc#NASDAQ">IRTC</a>)</li>
<li>Keros Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kros#NASDAQ">KROS</a>)</li>
<li>Liminal BioSciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmnl#NASDAQ">LMNL</a>)</li>
<li>Madrigal Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdgl#NASDAQ">MDGL</a>)</li>
<li>Moleculin Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mbrx#NASDAQ">MBRX</a>)</li>
<li>Neoleukin Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nltx#NASDAQ">NLTX</a>)</li>
<li>Oncorus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oncr#NASDAQ">ONCR</a>)</li>
<li>Orchard Therapeutics plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ortx#NASDAQ">ORTX</a>)</li>
<li>Otonomy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otic#NASDAQ">OTIC</a>)</li>
<li>Protara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tara#NASDAQ">TARA</a>)</li>
<li>Qualigen Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qlgn#NASDAQ">QLGN</a>)</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxrx#NASDAQ">RXRX</a>)</li>
<li>scPharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scph#NASDAQ">SCPH</a>)</li>
<li>Singular Genomics Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omic#NASDAQ">OMIC</a>)</li>
<li>Soleno Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slno#NASDAQ">SLNO</a>)</li>
<li>Spectrum Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sppi#NASDAQ">SPPI</a>)</li>
<li>Teligent, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlgt#NASDAQ">TLGT</a>)</li>
<li>TherapeuticsMD, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/txmd#NASDAQ">TXMD</a>)</li>
<li>Tiziana Life Sciences PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlsa#NASDAQ">TLSA</a>)</li>
<li>Trevena, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trvn#NASDAQ">TRVN</a>)</li>
<li>Trevi Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trvi#NASDAQ">TRVI</a>)</li>
<li>Universe Pharmaceuticals INC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upc#NASDAQ">UPC</a>)</li>
<li>VYNE Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vyne#NASDAQ">VYNE</a>)</li>
<li>X4 Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xfor#NASDAQ">XFOR</a>)</li>
</ul>
<h3>Stocks In Focus</h3>
<h3>Coherus Announces Positive Late-Stage Data From Lung Cancer Study</h3>
Coherus Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrs#NASDAQ">CHRS</a>) and Shanghai Junshi Biosciences announced positive interim results from the pivotal Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer.
The interim analysis met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival compared to chemotherapy alone.
Coherus shares were jumping 21.07% to $17.12 in premarket trading.
<h3>Paratek&#39;s Antibiotic Gets Orphan Drug Designation For Bacterial Infection</h3>
Paratek Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prtk#NASDAQ">PRTK</a>) said the Food and Administration has granted orphan drug designation for Nuzyra in the treatment of infections caused by nontuberculous mycobacteria.
This orphan drug designation includes NTM pulmonary disease caused by Mycobacterium abscessus complex, which is the focus of an ongoing Phase 2b study initiated by Paratek.
The stock was slipping 1.73% to $5.12 in premarket trading.
Related Link: <a href=" https://www.benzinga.com/general/biotech/21/08/22498723/the-week-ahead-in-biotech-fate-therapeutics-data-readout-renovorx-ipo-in-focus-amid-tapering-earn"> The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow </a>
<h3>Illumina Acquires Cancer Diagnostics Company Grail</h3>
Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) announced the acquisition of GRAIL, a health care company focused on life-saving early detection of multiple cancers. The company said it will hold GRAIL as a separate company during the European Commission&#39;s ongoing <a href="https://www.benzinga.com/government/21/07/22128324/illumina-grail-8b-merger-hit-by-european-commissions-in-depth-investigation?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29">regulatory review.</a>
Illumina first announced its intention to acquire GRAIL nearly a year ago, four years after it was spun off. GRAIL&#39;s Galleri blood test detects 50 different cancers before they are symptomatic.
The stock was down 0.46% at $508.26.
Click <a href="https://www.benzinga.com/fda-biotech#historical"> here </a> to access Benzinga&#39;s FDA Calendar.
<h3>Adagene Announces Clinical Study Collaboration For Evaluating ADG106-Keytruda Combo In Solid Tumor/Hematological Malignancies</h3>
Adagene Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adag#NASDAQ">ADAG</a>) announced that it has entered into a third clinical trial collaboration and supply agreement with Merck &amp; Co., Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>). The agreement includes an open-label, dose escalation and expansion clinical study of ADG106 in combination with Merck&#39;s Keytruda in advanced or metastatic solid and/or hematological malignancies.
See also:&nbsp;<a href="https://www.benzinga.com/money/cancer-insurance/">BEST CANCER INSURANCE</a>
<h3>On The Radar</h3>
<h3>Clinical Readouts</h3>
Fate Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fate#NASDAQ">FATE</a>) is scheduled to present at an investor event new Phase 1 data from FT516 and FT596 programs in relapsed/refractory lymphoma.
Plus Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pstv#NASDAQ">PSTV</a>) will present at the Conference on Brain Metastases, hosted by the Society for Neuro-Oncology, data from one planned clinical trial and one completed preclinical study evaluating its lead investigational drug, Rhenium-186 Nanoliposome for the treatment of leptomeningeal metastases.
Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/08/22236344/attention-biotech-investors-mark-your-calendar-for-august-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates </a>

Health Care

ABBV

ABSI

ACHV

ADAG

ADMA

ADPT

AKUS

ALKS

ANGN

APTX

ARNA

AVRO

AXSM

BMEA

BVXV

CBAY

CBIO

CFRX

CHRS

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CMPI

CMPX

CRNX

CTMX

EPZM

ESPR

FATE

FGEN

FLXN

GILD

HRTX

ILMN

INVA

IRTC

ISRG

KROS

LMNL

MBRX

MDGL

MRVI

NLTX

OMGA

OMIC

ONCR

ORTX

OTIC

PRTK

PSTV

Qualigen Therapeutics, Inc. - Common Stock

QLGN

REGN

RXRX

SCPH

SLNO

SPPI

TARA

TCRX

TLGT

TLSA

TRVI

TRVN

TXMD

VYNE

XFOR

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck

&nbsp;
<h3>Gainers</h3>
<ul>
<li>PharmaCyte Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMCB#NASDAQ">PMCB</a>) shares rose 119.0% to $7.49 during Wednesday&#39;s regular session. Trading volume for PharmaCyte Biotech&#39;s stock is 144.3 million as of 12:30 EST. This is 2009.46% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $12.0 million.</li>
<li>AzurRx BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZRX#NASDAQ">AZRX</a>) stock moved upwards by 29.93% to $0.69. Trading volume for AzurRx BioPharma&#39;s stock is 100.3 million as of 12:30 EST. This is 6527.88% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $63.8 million. As per the press release, Q2 earnings came out 2 days ago.</li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares rose 26.9% to $15.82. Trading volume for NRX Pharmaceuticals&#39;s stock is 5.4 million as of 12:30 EST. This is 121.36% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $758.2 million. As per the press release, Q2 earnings came out 2 days ago.</li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 24.46% to $8.75. The market value of their outstanding shares is at $110.6 million.</li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock moved upwards by 14.24% to $8.66. Trading volume for this security as of 12:30 EST is 596.3K, which is 119.54% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $207.3 million.</li>
<li>AcelRx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRX#NASDAQ">ACRX</a>) stock moved upwards by 13.33% to $1.06. Trading volume for this security as of 12:30 EST is 1.5 million, which is 70.94% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $126.1 million. As per the press release, Q2 earnings came out 2 days ago.</li>
</ul>
&nbsp;
&nbsp;
<h3>Losers</h3>
&nbsp;
<ul>
<li>Sesen Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SESN#NASDAQ">SESN</a>) stock decreased by 14.91% to $1.28 during Wednesday&#39;s regular session. Trading volume for Sesen Bio&#39;s stock is 65.4 million as of 12:30 EST. This is 488.39% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $251.8 million.</li>
<li>Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) stock declined by 10.11% to $24.25. As of 12:30 EST, Vaxcyte&#39;s stock is trading at a volume of 109.5K, which is 52.4% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $1.2 billion.</li>
<li>Avalon Globocare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVCO#NASDAQ">AVCO</a>) stock decreased by 8.82% to $0.92. Trading volume for this security as of 12:30 EST is 259.3K, which is 86.99% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $77.7 million.</li>
<li>Eyegate Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEG#NASDAQ">EYEG</a>) shares declined by 8.54% to $1.5. Eyegate Pharmaceuticals&#39;s stock is trading at a volume of 1.4 million shares as of 12:30 EST. This is 103.06% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $18.9 million. The company&#39;s, Q2 earnings came out 4 days ago.</li>
<li>Marinus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares fell 8.19% to $11.05. As of 12:30 EST, Marinus Pharmaceuticals&#39;s stock is trading at a volume of 338.4K, which is 160.17% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $406.0 million.</li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock decreased by 7.71% to $25.05. Trading volume for Renalytix&#39;s stock is 636.9K as of 12:30 EST. This is 814.97% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $904.6 million.</li>
</ul>
&nbsp;
&nbsp;

ACRX

AVCO

MRNS

PCVX

PMCB

SESN

XAIR

12 Health Care Stocks Moving In Wednesday's Intraday Session

Earnings

ABVC

ACAD

ACXP

ADVM

AGRX

AGTC

AKYA

APTO

ARAV

ARDS

ARDX

ASRT

ATAI

ATHA

ATNX

ATXI

AXDX

AYTU

BDSX

BIOC

BLPH

BXRX

CELU

CLBS

CLLS

DCPH

DFFN

DRMA

DRRX

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business

Comments

AB Corporate Bond ETF

Notizie

Ultime notizie per AB Corporate Bond ETF (NASDAQ:EYEG)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO